Helen W. Wheadon

21 Shelley Road
Glasgow, SCT G120ZD, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

The CD70/CD27 Axis in Tyrosine Kinase Inhibitor-Treated Chronic Phase Chronic Myeloid Leukemia Cells Is Not an Achilles Heel.

The CD70/CD27 Axis in Tyrosine Kinase Inhibitor-Treated Chronic Phase Chronic Myeloid Leukemia Cells Is Not an Achilles Heel.

Journal: Hematology reports

Published: March 11, 2026

Sequential BCR::ABL1 evaluation during dose de-escalation in peripheral blood is more predictive of TFR success than single assessment at dose de-escalation in either peripheral blood or bone marrow.

Sequential BCR::ABL1 evaluation during dose de-escalation in peripheral blood is more predictive of TFR success than single assessment at dose de-escalation in either peripheral blood or bone marrow.

Journal: Leukemia

Published: August 22, 2025

Selective small molecule targeting of KDM4 as a therapeutic strategy to reduce proliferation of acute myeloid leukaemia.

Selective small molecule targeting of KDM4 as a therapeutic strategy to reduce proliferation of acute myeloid leukaemia.

Journal: British journal of haematology

Published: July 17, 2025

Evaluation of current mouse in vivo models and advanced in vitro models for leukaemia research.

Evaluation of current mouse in vivo models and advanced in vitro models for leukaemia research.

Journal: Blood reviews

Published: April 15, 2025

Targeting MDM2 homodimer and heterodimer disruption with DRx-098D in TP53 wild-type and mutant cancer cells.

Targeting MDM2 homodimer and heterodimer disruption with DRx-098D in TP53 wild-type and mutant cancer cells.

Journal: Molecular therapy. Oncology

Published: February 27, 2025

Complexities of modeling the bone marrow microenvironment to facilitate hematopoietic research.

Complexities of modeling the bone marrow microenvironment to facilitate hematopoietic research.

Journal: Experimental hematology

Published: December 21, 2023

Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.

Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.

Journal: Cell communication and signaling : CCS

Published: July 04, 2023

Bioengineered niches that recreate physiological extracellular matrix organisation to support long-term haematopoietic stem cells.

Bioengineered niches that recreate physiological extracellular matrix organisation to support long-term haematopoietic stem cells.

Journal: Nature communications

Published: August 09, 2022

Leukaemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche.

Leukaemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche.

Journal: Nature communications

Published: April 29, 2022

BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia.

BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia.

Journal: Cell death discovery

Published: April 26, 2022

Micro-environment alterations through time leading to myeloid malignancies.

Micro-environment alterations through time leading to myeloid malignancies.

Journal: British journal of pharmacology

Published: November 04, 2021

Correction to: Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML.

Correction to: Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML.

Journal: Cell death discovery

Published: July 07, 2021

Showing 1-12 of 34

Last Updated: 09/26/2026